GlassScriptPhysician profile
Marc Mckinley
NPI 1225212285
$3,727.84
in general payments reported to CMS, 2019-2025
24 companies · $633 in 2025
The $633 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $148 · 2021: $393 · 2022: $618 · 2023: $835 · 2024: $801 · 2025: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.91 |
| Education | $112.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $641.38 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $476.15 | 2019-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $458.52 | 2022-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $274.40 | 2022-2025 | |
| Fresenius USA Marketing, INC. | $258.66 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Vifor Pharma, INC. | $197.43 | 2019-2025 | Veltassa |
| Travere Therapeutics, INC. | $194.93 | 2023-2025 | Filspari |
| Akebia Therapeutics INC | $167.16 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.08 | 2024-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $124.68 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $121.93 | 2022-2023 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $120.73 | 2024-2025 | |
| Nxstage Medical, INC. | $115.45 | 2021 | |
| Amgen INC. | $90.51 | 2022-2023 | Tavneos, Parsabiv |
| Baxter Healthcare | $73.29 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $65.97 | 2019-2024 | Jynarque |
| Mallinckrodt Enterprises LLC | $51.08 | 2019 | |
| Novo Nordisk INC | $38.36 | 2025 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $24.53 | 2023 | Krystexxa |
| Merck Sharp & Dohme LLC | $20.54 | 2025 | Verquvo |
| Chiesi USA, INC. | $20.13 | 2025 | Elfabrio |
| Scpharmaceuticals INC. | $19.99 | 2025 | |
| Lilly USA, LLC | $19.86 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $14.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Mckinley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.